Salk to Lead $41M ARPA-H Initiative to Make Ultrasound-Controlled Therapies a Reality
Salk Institute researcher Sreekanth Chalasani will lead a multi-institution ARPA-H program, funded up to $41.3 million over about 5.5 years, to advance sonogenetics—the use of ultrasound to control engineered cells—into a clinical therapy by building a protein toolkit, a wearable ultrasound delivery system, and preclinical data across partner sites toward trials, with potential applications such as peripheral neuropathies.